Smart Assistans AB has been acquired by Förenade Care AB
The private shareholders of Smart Assistans AB have sold the company to Förenade Care AB for an undisclosed consideration.
Smart Assistans provides personal care services for disabled adults, in compliance with the Swedish Act concerning Support and Services for Persons with Certain Functional Impairments. The company's services include assistance in practical tasks, as well as the promotion of patient well-being through joint social activities in various forms.
Based in Sweden, Förenade Care provides care and support services for people with disabilities. The company offers health care, social care and medical care services, in addition to operating care homes in Sweden. Förenade Care is part of Danish Förenade Group, a leading privately owned service company in the Nordic region, with approximately 8,000 employees.
Oaklins' team in Sweden advised the seller in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more